Brazil’s ANVISA approved the Butantan-DV single-dose dengue vaccine, developed by Butantan Institute, showing 91.6 percent efficacy amid record global dengue cases in 2024.
Brazil’s ANVISA approved the Butantan-DV single-dose dengue vaccine, developed by Butantan Institute, showing 91.6 percent efficacy amid record global dengue cases in 2024.